Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,439 | 200 | 1,214 |
| Samples | 631 | 117 | 499 |
| Peptides | 535 | 84 | 454 |
Function
CEMIP2 · Cell migration inducing hyaluronidase 2
This gene encodes a type II transmembrane protein that belongs to the interferon-induced transmembrane (IFITM) protein superfamily. The encoded protein functions as a cell surface hyaluronidase that cleaves extracellular high molecular weight hyaluronan into intermediate size fragments before internalization and degradation in the lysosome. It also has an interferon-mediated antiviral function in humans through activation of the JAK STAT signaling pathway. The activation of this gene by transcription factor SOX4 in breast cancer cells has been shown to mediate the pathological effects of SOX4 on cancer progression. Naturally occurring mutations in this gene are associated with autosomal recessive non-syndromic hearing loss. [provided by RefSeq, Mar 2017].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 513 amino-acid changes on canonical ENST00000377044 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CEMIP2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CEMIP2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 2/25 8% | 0/0 0% |
| Endometrial Carcinoma | 14/42 33% | 25/612 4% |
| Glioblastoma | 5/98 5% | 0/0 0% |
| Chordoma | 0/7 0% | 1/13 8% |
| Acute Myeloid Leukemia | 4/90 4% | 0/0 0% |
| Melanoma | 4/210 2% | 83/1899 4% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 4/133 3% |
| Colorectal Carcinoma | 16/143 11% | 72/3239 2% |
| Non-Small Cell Lung Carcinoma | 11/304 4% | 33/1390 2% |
| Thymic Epithelial Tumor | 0/0 0% | 1/39 3% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 17/810 2% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Cervical Carcinoma | 3/35 9% | 5/422 1% |
| Gastric Carcinoma | 0/74 0% | 32/1809 2% |
| Ewings Sarcoma | 2/63 3% | 3/262 1% |
| Other Solid Cancers | 0/94 0% | 24/1515 2% |
| Bladder Carcinoma | 0/58 0% | 15/956 2% |
| Hodgkins Lymphoma | 2/16 12% | 0/122 0% |
| Head and Neck Carcinoma | 3/85 4% | 21/1574 1% |
| Plasma Cell Myeloma | 2/44 5% | 3/305 1% |
| Neuroendocrine Tumour | 6/154 4% | 4/577 1% |
| Ovarian Carcinoma | 8/109 7% | 7/998 1% |
| Glioma | 4/52 8% | 25/2127 1% |
| Hepatocellular Carcinoma | 2/46 4% | 23/2210 1% |
| Germ Cell Tumour | 1/25 4% | 1/169 1% |
| Non-Cancerous | 0/104 0% | 9/830 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 7/752 1% |
| Esophageal Squamous Cell Carcinoma | 3/51 6% | 19/2550 1% |
| Thyroid Gland Carcinoma | 2/45 4% | 11/1592 1% |
| Other Sarcomas | 0/69 0% | 6/699 1% |
Mutation Distribution
Where CEMIP2 is mutated · all tissues, split by cell line vs tissue
How many mutations in CEMIP2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
Mutations
All 1,439 mutations in CEMIP2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|